| Recruiting | An Open Label Phase 2 Study of Total Neoadjuvant Therapy (TNT) Consisting of FLOT With Pembrolizumab and Short Gastroesophageal Junction (GEJ) Adenocarcinoma | Phase 2 | 2025-07-24 |
| Recruiting | Recurrent/Metastatic Olfactory Neuroblastoma: Evaluating the Efficacy and Safety of Nivolumab Recurrent/ Metastatic Olfactory Neuroblastoma | Phase 2 | 2025-04-15 |
| Completed | Trastuzumab Deruxtecan Plus Nivolumab Plus Capecitabine Plus Oxaliplatin for HER2 Low Gastric and Gastroesopha Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma | Phase 1 / Phase 2 | 2023-12-20 |
| Recruiting | TNT of SCRT+CAPOX vs SCRT+CAPOXIRI for Locally Advanced Rectal Cancer Locally Advanced Rectal Cancer | Phase 3 | 2022-11-21 |
| Completed | Clinical Study of Regorafenib and Nivolumab Plus Chemotherapy Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma | Phase 1 / Phase 2 | 2022-06-06 |
| Active Not Recruiting | Phase 2 Study of Trastuzumab Deruxtecan in the Neoadjuvant Treatment, or Trastuzumab Deruxtecan Plus Capecitab Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma | Phase 2 | 2022-01-31 |
| Active Not Recruiting | An Open Label Phase 2 Study to Evaluate the Safety and Efficacy of Lenvatinib With Pembrolizumab or Lenvatinib Gastric Cancer | Phase 2 | 2021-11-11 |
| Completed | Olaparib Monotherapy and Olaparib + Pembrolizumab Combination Therapy for Ovarian Cancer Ovarian Cancer | Phase 2 | 2020-12-01 |
| Not Yet Recruiting | Efficacy and Safety of CRT, Durvalumab and Surgery for SST Superior Sulcus Tumor, Non-small Cell Lung Cancer Stage IIB, Non Small Cell Lung Cancer Stage III | Phase 3 | 2020-09-01 |
| Completed | Initial Attack on Latent Metastasis Using TAS-102 for ct DNA Identified Colorectal Cancer Patients After Curat Colorectal Neoplasms, Trifluridine and Tipiracil, Circulating Tumor DNA | Phase 3 | 2020-07-08 |
| Completed | Darolutamide in Patients With Androgen Receptor-Positive Salivary Gland Carcinoma (DISCOVARY) Salivary Gland Cancer | Phase 2 | 2020-04-17 |
| Recruiting | Surgery Plus Chemo Versus Chemoradiotherapy Followed by Surgery Plus Chemo for Locally Recurrent Rectal Cancer Rectal Cancer Recurrent | Phase 3 | 2019-10-01 |
| Active Not Recruiting | Nivolumab Plus Lenvatinib Against Anaplastic Thyroid Cancer (NAVIGATION) Anaplastic Thyroid Cancer | Phase 2 | 2019-07-02 |
| Completed | Lenvatinib and Pembrolizumab Simultaneous Combination Study Advanced Gastric Cancer | Phase 2 | 2018-10-03 |